Ian Phillips, who joined KGI in February 2006, received his PhD and DSc in pharmacology at the University of Birmingham in the United Kingdom. He was a postdoctoral fellow at the University of Michigan and an instructor and fellow in the Division of Biology at the California Institute of Technology. From 1970-1980, he rose to Professor of Physiology at the University of Iowa. In 1977, as a Humboldt Foundation Scholar, Phillips spent a year at the University of Heidelberg in Germany and at the University of Zurich in Switzerland. He discovered the brain renin angiotensin system, a finding important to hypertension, stroke, and development of new drugs.
In 1989, Phillips served as Program Director of Neurobiology at the National Science Foundation in Washington, DC. He worked at the White House Office of Technology on “The Decade of the Brain.” In 1980 he was at the National Institutes of Health (NIH). From 1980-2002, Phillips was Chairman of the Department of Physiology at the University of Florida. He built a modern gene-oriented department and founded the Division of Functional Genomics. In 2002, Phillips was appointed Vice President for Research at the University of South Florida, Tampa. As Vice President he increased the economic impact of high tech science in Southwest Florida, and constructed a new research building and business incubator in the USF Research Park.
In 2006, Phillips joined KGI, where he was appointed Norris Professor of Applied Life Sciences and founding director of the Center for Rare Disease Therapies. He also founded the Postbac Premedical Certificate (PPC) and the Master of Science in Applied Life Sciences programs.
Among his career honors, Phillips was awarded the 2002 Christopher Columbus Award for Science and Technology (US Congress), the 1989 Lucian Award (McGill University) for research in circulatory disease, two Howard Hughes Medical Institute grants, and a MERIT award from NIH (10 years of funding). He was elected Fellow of the American Heart Association (FAHA), Fellow of the American Association for the Advancement of Science (AAAS), and member of the US National Academy of Inventors. During his career, Phillips has published 12 books and more than 350 papers and reviews. The impact of his work is high (h-index = 77 with 18,743 citations). He has taught over 3,000 medical students and trained 40 PhD students and postdoctoral fellows.
At KGI, Phillips teaches Writing an Orphan Drug Designation for the FDA, Advances in Gene and Cell Therapy, Writing and Editing Professional Papers, and Molecular Basis of Medicine. He teaches in both the Henry E. Riggs School of Applied Life Sciences and the School of Pharmacy and Health Sciences. His current research is on gene switches for gene therapy, and on increasing Stem cell production.
Functions of angiotensin in the central nervous system
IM Phillips, Annual Review of Physiology 49 (1), 413-433, 1987 (cited by 710)
Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction
YL Tang, Q Zhao, X Qin, L Shen, L Cheng, J Ge, MI Phillips
The Annals of thoracic surgery 80 (1), 229-237, 2005 (cited by 363)
Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium, YL Tang, Q Zhao, YC Zhang, L Cheng, M Liu, J Shi, YZ Yang, C Pan, J Ge, Regulatory peptides 117 (1), 3-10, 2004 (cited by 359)
Levels of angiotensin and molecular biology of the tissue renin angiotensin systems, M Ian Phillips, EA Speakman, B Kimura, Regulatory peptides 43 (1), 1-20, 1993 (cited by 329)
Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation, DY Li, YC Zhang, MI Philips, T Sawamura, JL Mehta
Circulation research 84 (9), 1043-1049, 1999 (cited by 320)
Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector, YL Tang, Y Tang, YC Zhang, K Qian, L Shen, MI Phillips, Journal of the American College of Cardiology 46 (7), 1339-1350, 2005 (cited by 278)
Angiotensin II as a pro-inflammatory mediator.
MI Phillips, S Kagiyama, Current opinion in investigational drugs (London, England: 2000) 3 (4), 569-577, 2002 (cited by 204)
Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression
YL Tang, W Zhu, M Cheng, L Chen, J Zhang, T Sun, R Kishore, MI Phillips, Circulation research 104 (10), 1209-1216, 2009 (cited by 180)
The multiple actions of angiotensin II in atherosclerosis
KM Schmidt-Ott, S Kagiyama, MI Phillips, Regulatory peptides 93 (1), 65-77, 2000 (cited by 166)
Brain renin angiotensin in disease
MI Phillips, EM De Oliveira, Journal of molecular medicine 86 (6), 715-722, 2008 (cited by 106)
Celebrating 25 years of innovation! 25.kgi.edu.